U.S. Physical Therapy (USPH) Stock Looks Overvalued On Sales As 3 Year Returns Stay Weak

U.S. Physical Therapy stock has climbed 15.8% over the past year, but investors who have held it for three years are still facing a loss of about 29.3%. The latest valuation checks suggest the shares lean expensive on market multiples rather than offering an obvious bargain.

• Over the past three years, U.S. Physical Therapy has delivered a total return that is down 29.3%, which raises questions about how much of a recovery is already reflected in today’s share price.
• Future growth in patient volumes and reimbursement rates can support higher earnings over time. However, any pressure on clinic level margins or higher operating costs may weigh on what investors are willing to pay for the stock.
• With a value score of 3 out of 6, U.S. Physical Therapy screens as a mixed picture rather than clearly cheap or clearly overvalued across the broader set of valuation checks.

The issue now is whether the recent share price strength in U.S. Physical Therapy leaves enough upside to compensate for the risks that still concern valuation focused investors.

Find out why U.S. Physical Therapy's 15.8% return over the last year is lagging behind its peers.

Has U.S. Physical Therapy Run Too Far on Sales?

P/S can be a useful check for U.S. Physical Therapy because revenue is a cleaner starting point than earnings in a service heavy healthcare business.

The stock trades on a P/S of 1.5x, which sits slightly above the Healthcare industry average of 1.4x but a bit below the peer group at 1.7x. On a more tailored view, the fair P/S ratio implied by broader fundamentals is 0.7x. This is materially lower than where U.S. Physical Therapy currently trades and suggests the market is putting a higher value on each dollar of revenue than this framework supports.

Even allowing for differences between individual operators, the gap between the 1.5x current P/S and the 0.7x fair ratio indicates a stock that is pricing in a full set of positives on revenue quality and risk.

On this P/S check, U.S. Physical Therapy appears overvalued relative to what the fair ratio model suggests.

See what the numbers say about this price — find out in our valuation breakdown.

The U.S. Physical Therapy Narrative: What Would Justify Today's Price?

For U.S. Physical Therapy, Simply Wall St Narratives pick up where this valuation puzzle leaves off by spelling out which future paths for growth, margins and earnings would need to play out for the stock to be worth materially more or materially less than today’s price. These narratives sit on the company’s Community page.

Each narrative sets out U.S. Physical Therapy's fair value as a thesis about the business that can be revisited over time rather than as a single static number.

If you have a clear, number driven view on where U.S. Physical Therapy's growth, margins and execution go from here, consider sharing a Narrative to put your thesis on record and see how it stacks up as new results arrive.

Do you think there's more to the story for U.S. Physical Therapy? Head over to our Community to see what others are saying!

The Bottom Line

For U.S. Physical Therapy, the current market multiples point to an overvalued stock rather than a clear bargain. The key question is whether revenue quality, patient volumes and reimbursement can progress in a way that fully supports this richer P/S level without putting clinic margins under strain. For now, the valuation picture looks mixed and depends on whether the market is correctly anticipating steadier earnings power or paying too much in advance for that outcome.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com